Cellectis (CLLS) Revenue Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.24% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.82% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 19.04% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3,790.58% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -45.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.78% |
| Dec 31, 2025 | -37.75% |
| Sep 30, 2025 | 117.11% |
| Jun 30, 2025 | 107.48% |
| Mar 31, 2025 | 135.31% |
| Dec 31, 2024 | 7,118.37% |
| Sep 30, 2024 | 10,351.61% |
| Jun 30, 2024 | 4,428.65% |
| Mar 31, 2024 | 3,157.55% |
| Dec 31, 2023 | -98.23% |
| Sep 30, 2023 | -11.43% |
| Jun 30, 2023 | -86.38% |
| Mar 31, 2023 | -91.65% |
| Dec 31, 2022 | 56.15% |
| Sep 30, 2022 | -97.89% |
| Jun 30, 2022 | -88.31% |
| Mar 31, 2022 | -93.50% |
| Dec 31, 2021 | -24.82% |
| Sep 30, 2021 | 34.52% |
| Jun 30, 2021 | 285.38% |
| Mar 31, 2021 | -48.93% |
| Dec 31, 2020 | 208.59% |
| Sep 30, 2020 | -27.19% |
| Jun 30, 2020 | 151.74% |
| Mar 31, 2020 | 4,738.61% |
| Dec 31, 2019 | 356.92% |
| Sep 30, 2019 | 836.75% |
| Jun 30, 2019 | -77.18% |
| Mar 31, 2019 | -82.85% |
| Dec 31, 2018 | -85.99% |
| Sep 30, 2018 | -85.20% |
| Jun 30, 2018 | -22.25% |
| Mar 31, 2018 | -10.36% |
| Dec 31, 2017 | -15.72% |
| Sep 30, 2017 | -45.66% |
| Jun 30, 2017 | 862.74% |
| Mar 31, 2017 | -12.46% |
| Dec 31, 2016 | -77.35% |
| Sep 30, 2016 | 33.27% |
| Jun 30, 2016 | -91.67% |
| Mar 31, 2016 | -19.17% |